nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—CYP3A4—Thiotepa—urinary bladder cancer	0.06	0.402	CbGbCtD
Guanfacine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0335	0.224	CbGbCtD
Guanfacine—CYP2C9—Cisplatin—urinary bladder cancer	0.0285	0.191	CbGbCtD
Guanfacine—NISCH—Podofilox—Etoposide—urinary bladder cancer	0.0192	1	CbGdCrCtD
Guanfacine—CYP2C19—urine—urinary bladder cancer	0.0171	0.157	CbGeAlD
Guanfacine—CYP3A4—Etoposide—urinary bladder cancer	0.0163	0.109	CbGbCtD
Guanfacine—CYP2C9—urine—urinary bladder cancer	0.0132	0.122	CbGeAlD
Guanfacine—Diclofenac—UGT2B7—urinary bladder cancer	0.0129	0.578	CrCbGaD
Guanfacine—NISCH—prostate gland—urinary bladder cancer	0.0126	0.116	CbGeAlD
Guanfacine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0111	0.0743	CbGbCtD
Guanfacine—CYP3A4—urine—urinary bladder cancer	0.0101	0.0929	CbGeAlD
Guanfacine—NISCH—smooth muscle tissue—urinary bladder cancer	0.00894	0.0823	CbGeAlD
Guanfacine—NISCH—urethra—urinary bladder cancer	0.00846	0.0779	CbGeAlD
Guanfacine—Diclofenac—CXCL8—urinary bladder cancer	0.00729	0.327	CrCbGaD
Guanfacine—NISCH—vagina—urinary bladder cancer	0.00624	0.0574	CbGeAlD
Guanfacine—ADRA2A—prostate gland—urinary bladder cancer	0.0046	0.0424	CbGeAlD
Guanfacine—NISCH—lymph node—urinary bladder cancer	0.00403	0.0371	CbGeAlD
Guanfacine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00389	0.0358	CbGeAlD
Guanfacine—ADRA2A—urethra—urinary bladder cancer	0.00308	0.0284	CbGeAlD
Guanfacine—CYP2C19—vagina—urinary bladder cancer	0.00303	0.0279	CbGeAlD
Guanfacine—CYP2C9—female reproductive system—urinary bladder cancer	0.00259	0.0239	CbGeAlD
Guanfacine—ADRA2A—female reproductive system—urinary bladder cancer	0.00251	0.0231	CbGeAlD
Guanfacine—CYP3A4—renal system—urinary bladder cancer	0.00247	0.0227	CbGeAlD
Guanfacine—ADRA2A—vagina—urinary bladder cancer	0.00227	0.0209	CbGeAlD
Guanfacine—Diclofenac—PTGS2—urinary bladder cancer	0.00213	0.0953	CrCbGaD
Guanfacine—CYP3A4—female reproductive system—urinary bladder cancer	0.00198	0.0182	CbGeAlD
Guanfacine—ADRA2A—lymph node—urinary bladder cancer	0.00147	0.0135	CbGeAlD
Guanfacine—Insomnia—Fluorouracil—urinary bladder cancer	0.00117	0.0017	CcSEcCtD
Guanfacine—Somnolence—Gemcitabine—urinary bladder cancer	0.00116	0.0017	CcSEcCtD
Guanfacine—Affect lability—Doxorubicin—urinary bladder cancer	0.00116	0.00169	CcSEcCtD
Guanfacine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00116	0.00168	CcSEcCtD
Guanfacine—Discomfort—Etoposide—urinary bladder cancer	0.00115	0.00168	CcSEcCtD
Guanfacine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00115	0.00167	CcSEcCtD
Guanfacine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00115	0.00167	CcSEcCtD
Guanfacine—Somnolence—Fluorouracil—urinary bladder cancer	0.00115	0.00167	CcSEcCtD
Guanfacine—Hypotension—Cisplatin—urinary bladder cancer	0.00114	0.00166	CcSEcCtD
Guanfacine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00114	0.00166	CcSEcCtD
Guanfacine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00113	0.00165	CcSEcCtD
Guanfacine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00113	0.00164	CcSEcCtD
Guanfacine—Fatigue—Gemcitabine—urinary bladder cancer	0.00113	0.00164	CcSEcCtD
Guanfacine—Confusional state—Etoposide—urinary bladder cancer	0.00113	0.00164	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00113	0.00164	CcSEcCtD
Guanfacine—Constipation—Gemcitabine—urinary bladder cancer	0.00112	0.00163	CcSEcCtD
Guanfacine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00112	0.00163	CcSEcCtD
Guanfacine—Asthenia—Thiotepa—urinary bladder cancer	0.00112	0.00163	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00111	0.00162	CcSEcCtD
Guanfacine—Asthma—Epirubicin—urinary bladder cancer	0.0011	0.0016	CcSEcCtD
Guanfacine—Dysphagia—Epirubicin—urinary bladder cancer	0.0011	0.0016	CcSEcCtD
Guanfacine—Pruritus—Thiotepa—urinary bladder cancer	0.0011	0.0016	CcSEcCtD
Guanfacine—Paraesthesia—Cisplatin—urinary bladder cancer	0.0011	0.0016	CcSEcCtD
Guanfacine—Tachycardia—Etoposide—urinary bladder cancer	0.00109	0.00159	CcSEcCtD
Guanfacine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00109	0.00159	CcSEcCtD
Guanfacine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00109	0.00158	CcSEcCtD
Guanfacine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00109	0.00158	CcSEcCtD
Guanfacine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00108	0.00157	CcSEcCtD
Guanfacine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00108	0.00157	CcSEcCtD
Guanfacine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00108	0.00157	CcSEcCtD
Guanfacine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00108	0.00157	CcSEcCtD
Guanfacine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00107	0.00155	CcSEcCtD
Guanfacine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00106	0.00154	CcSEcCtD
Guanfacine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00106	0.00154	CcSEcCtD
Guanfacine—Drowsiness—Methotrexate—urinary bladder cancer	0.00105	0.00153	CcSEcCtD
Guanfacine—Hypotension—Etoposide—urinary bladder cancer	0.00105	0.00152	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00104	0.00152	CcSEcCtD
Guanfacine—Dizziness—Thiotepa—urinary bladder cancer	0.00103	0.0015	CcSEcCtD
Guanfacine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00102	0.00149	CcSEcCtD
Guanfacine—Dysphagia—Doxorubicin—urinary bladder cancer	0.00102	0.00149	CcSEcCtD
Guanfacine—Asthma—Doxorubicin—urinary bladder cancer	0.00102	0.00149	CcSEcCtD
Guanfacine—Pollakiuria—Epirubicin—urinary bladder cancer	0.00102	0.00148	CcSEcCtD
Guanfacine—Sweating—Methotrexate—urinary bladder cancer	0.00101	0.00147	CcSEcCtD
Guanfacine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00101	0.00146	CcSEcCtD
Guanfacine—Paraesthesia—Etoposide—urinary bladder cancer	0.001	0.00146	CcSEcCtD
Guanfacine—Weight increased—Epirubicin—urinary bladder cancer	0.001	0.00146	CcSEcCtD
Guanfacine—Dyspnoea—Etoposide—urinary bladder cancer	0.000997	0.00145	CcSEcCtD
Guanfacine—Somnolence—Etoposide—urinary bladder cancer	0.000995	0.00145	CcSEcCtD
Guanfacine—Vomiting—Thiotepa—urinary bladder cancer	0.00099	0.00144	CcSEcCtD
Guanfacine—Drowsiness—Epirubicin—urinary bladder cancer	0.000983	0.00143	CcSEcCtD
Guanfacine—Rash—Thiotepa—urinary bladder cancer	0.000982	0.00143	CcSEcCtD
Guanfacine—Dermatitis—Thiotepa—urinary bladder cancer	0.000981	0.00143	CcSEcCtD
Guanfacine—Headache—Thiotepa—urinary bladder cancer	0.000976	0.00142	CcSEcCtD
Guanfacine—Decreased appetite—Etoposide—urinary bladder cancer	0.000973	0.00142	CcSEcCtD
Guanfacine—Fatigue—Etoposide—urinary bladder cancer	0.000965	0.0014	CcSEcCtD
Guanfacine—Constipation—Etoposide—urinary bladder cancer	0.000957	0.00139	CcSEcCtD
Guanfacine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000956	0.00139	CcSEcCtD
Guanfacine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000949	0.00138	CcSEcCtD
Guanfacine—Sweating—Epirubicin—urinary bladder cancer	0.000943	0.00137	CcSEcCtD
Guanfacine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000943	0.00137	CcSEcCtD
Guanfacine—Asthenia—Gemcitabine—urinary bladder cancer	0.00094	0.00137	CcSEcCtD
Guanfacine—Weight increased—Doxorubicin—urinary bladder cancer	0.000929	0.00135	CcSEcCtD
Guanfacine—Pruritus—Gemcitabine—urinary bladder cancer	0.000927	0.00135	CcSEcCtD
Guanfacine—Nausea—Thiotepa—urinary bladder cancer	0.000925	0.00135	CcSEcCtD
Guanfacine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000922	0.00134	CcSEcCtD
Guanfacine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000915	0.00133	CcSEcCtD
Guanfacine—Pruritus—Fluorouracil—urinary bladder cancer	0.000911	0.00133	CcSEcCtD
Guanfacine—Drowsiness—Doxorubicin—urinary bladder cancer	0.00091	0.00132	CcSEcCtD
Guanfacine—Visual impairment—Methotrexate—urinary bladder cancer	0.000909	0.00132	CcSEcCtD
Guanfacine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.0009	0.00131	CcSEcCtD
Guanfacine—Bradycardia—Epirubicin—urinary bladder cancer	0.000899	0.00131	CcSEcCtD
Guanfacine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000896	0.0013	CcSEcCtD
Guanfacine—Rhinitis—Epirubicin—urinary bladder cancer	0.000885	0.00129	CcSEcCtD
Guanfacine—Abdominal pain—Etoposide—urinary bladder cancer	0.000884	0.00129	CcSEcCtD
Guanfacine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000884	0.00129	CcSEcCtD
Guanfacine—Eye disorder—Methotrexate—urinary bladder cancer	0.000881	0.00128	CcSEcCtD
Guanfacine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000881	0.00128	CcSEcCtD
Guanfacine—Tinnitus—Methotrexate—urinary bladder cancer	0.000879	0.00128	CcSEcCtD
Guanfacine—Asthenia—Cisplatin—urinary bladder cancer	0.000876	0.00128	CcSEcCtD
Guanfacine—Sweating—Doxorubicin—urinary bladder cancer	0.000872	0.00127	CcSEcCtD
Guanfacine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000852	0.00124	CcSEcCtD
Guanfacine—Dizziness—Fluorouracil—urinary bladder cancer	0.000852	0.00124	CcSEcCtD
Guanfacine—Visual impairment—Epirubicin—urinary bladder cancer	0.000851	0.00124	CcSEcCtD
Guanfacine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000836	0.00122	CcSEcCtD
Guanfacine—Alopecia—Methotrexate—urinary bladder cancer	0.000833	0.00121	CcSEcCtD
Guanfacine—Vomiting—Gemcitabine—urinary bladder cancer	0.000833	0.00121	CcSEcCtD
Guanfacine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000831	0.00121	CcSEcCtD
Guanfacine—Rash—Gemcitabine—urinary bladder cancer	0.000826	0.0012	CcSEcCtD
Guanfacine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000825	0.0012	CcSEcCtD
Guanfacine—Eye disorder—Epirubicin—urinary bladder cancer	0.000825	0.0012	CcSEcCtD
Guanfacine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000824	0.0012	CcSEcCtD
Guanfacine—Tinnitus—Epirubicin—urinary bladder cancer	0.000823	0.0012	CcSEcCtD
Guanfacine—Headache—Gemcitabine—urinary bladder cancer	0.000821	0.00119	CcSEcCtD
Guanfacine—Vomiting—Fluorouracil—urinary bladder cancer	0.000819	0.00119	CcSEcCtD
Guanfacine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000819	0.00119	CcSEcCtD
Guanfacine—Rash—Fluorouracil—urinary bladder cancer	0.000812	0.00118	CcSEcCtD
Guanfacine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000811	0.00118	CcSEcCtD
Guanfacine—Headache—Fluorouracil—urinary bladder cancer	0.000807	0.00117	CcSEcCtD
Guanfacine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000804	0.00117	CcSEcCtD
Guanfacine—Asthenia—Etoposide—urinary bladder cancer	0.000803	0.00117	CcSEcCtD
Guanfacine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000797	0.00116	CcSEcCtD
Guanfacine—Pruritus—Etoposide—urinary bladder cancer	0.000791	0.00115	CcSEcCtD
Guanfacine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000787	0.00115	CcSEcCtD
Guanfacine—Alopecia—Epirubicin—urinary bladder cancer	0.00078	0.00114	CcSEcCtD
Guanfacine—Nausea—Gemcitabine—urinary bladder cancer	0.000778	0.00113	CcSEcCtD
Guanfacine—Vomiting—Cisplatin—urinary bladder cancer	0.000776	0.00113	CcSEcCtD
Guanfacine—Vision blurred—Methotrexate—urinary bladder cancer	0.000774	0.00113	CcSEcCtD
Guanfacine—Rash—Cisplatin—urinary bladder cancer	0.00077	0.00112	CcSEcCtD
Guanfacine—Dermatitis—Cisplatin—urinary bladder cancer	0.000769	0.00112	CcSEcCtD
Guanfacine—Diarrhoea—Etoposide—urinary bladder cancer	0.000765	0.00111	CcSEcCtD
Guanfacine—Nausea—Fluorouracil—urinary bladder cancer	0.000765	0.00111	CcSEcCtD
Guanfacine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000763	0.00111	CcSEcCtD
Guanfacine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000762	0.00111	CcSEcCtD
Guanfacine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000761	0.00111	CcSEcCtD
Guanfacine—Tension—Epirubicin—urinary bladder cancer	0.000754	0.0011	CcSEcCtD
Guanfacine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000752	0.0011	CcSEcCtD
Guanfacine—Nervousness—Epirubicin—urinary bladder cancer	0.000746	0.00109	CcSEcCtD
Guanfacine—Malaise—Methotrexate—urinary bladder cancer	0.00074	0.00108	CcSEcCtD
Guanfacine—Dizziness—Etoposide—urinary bladder cancer	0.00074	0.00108	CcSEcCtD
Guanfacine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000739	0.00108	CcSEcCtD
Guanfacine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000738	0.00107	CcSEcCtD
Guanfacine—Vertigo—Methotrexate—urinary bladder cancer	0.000738	0.00107	CcSEcCtD
Guanfacine—Nausea—Cisplatin—urinary bladder cancer	0.000725	0.00106	CcSEcCtD
Guanfacine—Vision blurred—Epirubicin—urinary bladder cancer	0.000724	0.00105	CcSEcCtD
Guanfacine—Alopecia—Doxorubicin—urinary bladder cancer	0.000722	0.00105	CcSEcCtD
Guanfacine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000713	0.00104	CcSEcCtD
Guanfacine—Convulsion—Methotrexate—urinary bladder cancer	0.000711	0.00104	CcSEcCtD
Guanfacine—Vomiting—Etoposide—urinary bladder cancer	0.000711	0.00104	CcSEcCtD
Guanfacine—Agitation—Epirubicin—urinary bladder cancer	0.000706	0.00103	CcSEcCtD
Guanfacine—Rash—Etoposide—urinary bladder cancer	0.000705	0.00103	CcSEcCtD
Guanfacine—Dermatitis—Etoposide—urinary bladder cancer	0.000705	0.00103	CcSEcCtD
Guanfacine—Headache—Etoposide—urinary bladder cancer	0.000701	0.00102	CcSEcCtD
Guanfacine—Chest pain—Methotrexate—urinary bladder cancer	0.000699	0.00102	CcSEcCtD
Guanfacine—Myalgia—Methotrexate—urinary bladder cancer	0.000699	0.00102	CcSEcCtD
Guanfacine—Arthralgia—Methotrexate—urinary bladder cancer	0.000699	0.00102	CcSEcCtD
Guanfacine—Tension—Doxorubicin—urinary bladder cancer	0.000698	0.00102	CcSEcCtD
Guanfacine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000696	0.00101	CcSEcCtD
Guanfacine—Malaise—Epirubicin—urinary bladder cancer	0.000693	0.00101	CcSEcCtD
Guanfacine—Discomfort—Methotrexate—urinary bladder cancer	0.000691	0.00101	CcSEcCtD
Guanfacine—Nervousness—Doxorubicin—urinary bladder cancer	0.000691	0.001	CcSEcCtD
Guanfacine—Vertigo—Epirubicin—urinary bladder cancer	0.00069	0.001	CcSEcCtD
Guanfacine—Syncope—Epirubicin—urinary bladder cancer	0.000689	0.001	CcSEcCtD
Guanfacine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000684	0.000995	CcSEcCtD
Guanfacine—Palpitations—Epirubicin—urinary bladder cancer	0.000679	0.000988	CcSEcCtD
Guanfacine—Confusional state—Methotrexate—urinary bladder cancer	0.000676	0.000983	CcSEcCtD
Guanfacine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000675	0.000983	CcSEcCtD
Guanfacine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00067	0.000975	CcSEcCtD
Guanfacine—Convulsion—Epirubicin—urinary bladder cancer	0.000666	0.000969	CcSEcCtD
Guanfacine—Nausea—Etoposide—urinary bladder cancer	0.000665	0.000967	CcSEcCtD
Guanfacine—Hypertension—Epirubicin—urinary bladder cancer	0.000663	0.000965	CcSEcCtD
Guanfacine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00066	0.00096	CcSEcCtD
Guanfacine—Myalgia—Epirubicin—urinary bladder cancer	0.000654	0.000952	CcSEcCtD
Guanfacine—Chest pain—Epirubicin—urinary bladder cancer	0.000654	0.000952	CcSEcCtD
Guanfacine—Arthralgia—Epirubicin—urinary bladder cancer	0.000654	0.000952	CcSEcCtD
Guanfacine—Agitation—Doxorubicin—urinary bladder cancer	0.000653	0.000951	CcSEcCtD
Guanfacine—Anxiety—Epirubicin—urinary bladder cancer	0.000652	0.000949	CcSEcCtD
Guanfacine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000648	0.000943	CcSEcCtD
Guanfacine—Discomfort—Epirubicin—urinary bladder cancer	0.000646	0.000941	CcSEcCtD
Guanfacine—Malaise—Doxorubicin—urinary bladder cancer	0.000641	0.000933	CcSEcCtD
Guanfacine—Dry mouth—Epirubicin—urinary bladder cancer	0.00064	0.000931	CcSEcCtD
Guanfacine—Vertigo—Doxorubicin—urinary bladder cancer	0.000639	0.00093	CcSEcCtD
Guanfacine—Syncope—Doxorubicin—urinary bladder cancer	0.000638	0.000928	CcSEcCtD
Guanfacine—Confusional state—Epirubicin—urinary bladder cancer	0.000632	0.00092	CcSEcCtD
Guanfacine—Palpitations—Doxorubicin—urinary bladder cancer	0.000628	0.000914	CcSEcCtD
Guanfacine—Oedema—Epirubicin—urinary bladder cancer	0.000627	0.000913	CcSEcCtD
Guanfacine—Hypotension—Methotrexate—urinary bladder cancer	0.000626	0.000911	CcSEcCtD
Guanfacine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000625	0.000909	CcSEcCtD
Guanfacine—Shock—Epirubicin—urinary bladder cancer	0.000617	0.000898	CcSEcCtD
Guanfacine—Convulsion—Doxorubicin—urinary bladder cancer	0.000616	0.000897	CcSEcCtD
Guanfacine—Hypertension—Doxorubicin—urinary bladder cancer	0.000614	0.000893	CcSEcCtD
Guanfacine—Tachycardia—Epirubicin—urinary bladder cancer	0.000612	0.000891	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000611	0.000889	CcSEcCtD
Guanfacine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000606	0.000882	CcSEcCtD
Guanfacine—Insomnia—Methotrexate—urinary bladder cancer	0.000606	0.000882	CcSEcCtD
Guanfacine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000605	0.000881	CcSEcCtD
Guanfacine—Myalgia—Doxorubicin—urinary bladder cancer	0.000605	0.000881	CcSEcCtD
Guanfacine—Chest pain—Doxorubicin—urinary bladder cancer	0.000605	0.000881	CcSEcCtD
Guanfacine—Anxiety—Doxorubicin—urinary bladder cancer	0.000603	0.000878	CcSEcCtD
Guanfacine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000602	0.000876	CcSEcCtD
Guanfacine—Discomfort—Doxorubicin—urinary bladder cancer	0.000598	0.00087	CcSEcCtD
Guanfacine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000597	0.000869	CcSEcCtD
Guanfacine—Somnolence—Methotrexate—urinary bladder cancer	0.000596	0.000867	CcSEcCtD
Guanfacine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000592	0.000862	CcSEcCtD
Guanfacine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00059	0.000858	CcSEcCtD
Guanfacine—Hypotension—Epirubicin—urinary bladder cancer	0.000586	0.000853	CcSEcCtD
Guanfacine—Confusional state—Doxorubicin—urinary bladder cancer	0.000585	0.000851	CcSEcCtD
Guanfacine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000583	0.000848	CcSEcCtD
Guanfacine—Oedema—Doxorubicin—urinary bladder cancer	0.00058	0.000844	CcSEcCtD
Guanfacine—Fatigue—Methotrexate—urinary bladder cancer	0.000578	0.000841	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000571	0.000832	CcSEcCtD
Guanfacine—Shock—Doxorubicin—urinary bladder cancer	0.000571	0.000831	CcSEcCtD
Guanfacine—Insomnia—Epirubicin—urinary bladder cancer	0.000567	0.000825	CcSEcCtD
Guanfacine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000566	0.000824	CcSEcCtD
Guanfacine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000563	0.00082	CcSEcCtD
Guanfacine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000561	0.000816	CcSEcCtD
Guanfacine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000559	0.000814	CcSEcCtD
Guanfacine—Somnolence—Epirubicin—urinary bladder cancer	0.000557	0.000811	CcSEcCtD
Guanfacine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000552	0.000804	CcSEcCtD
Guanfacine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000552	0.000803	CcSEcCtD
Guanfacine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000548	0.000797	CcSEcCtD
Guanfacine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000545	0.000793	CcSEcCtD
Guanfacine—Hypotension—Doxorubicin—urinary bladder cancer	0.000542	0.000789	CcSEcCtD
Guanfacine—Fatigue—Epirubicin—urinary bladder cancer	0.000541	0.000787	CcSEcCtD
Guanfacine—Constipation—Epirubicin—urinary bladder cancer	0.000536	0.00078	CcSEcCtD
Guanfacine—Abdominal pain—Methotrexate—urinary bladder cancer	0.00053	0.000771	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000529	0.000769	CcSEcCtD
Guanfacine—Insomnia—Doxorubicin—urinary bladder cancer	0.000525	0.000764	CcSEcCtD
Guanfacine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000521	0.000758	CcSEcCtD
Guanfacine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000517	0.000753	CcSEcCtD
Guanfacine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000517	0.000752	CcSEcCtD
Guanfacine—Somnolence—Doxorubicin—urinary bladder cancer	0.000516	0.000751	CcSEcCtD
Guanfacine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000513	0.000746	CcSEcCtD
Guanfacine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000511	0.000743	CcSEcCtD
Guanfacine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000504	0.000734	CcSEcCtD
Guanfacine—Fatigue—Doxorubicin—urinary bladder cancer	0.0005	0.000728	CcSEcCtD
Guanfacine—Constipation—Doxorubicin—urinary bladder cancer	0.000496	0.000722	CcSEcCtD
Guanfacine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000496	0.000721	CcSEcCtD
Guanfacine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000494	0.000719	CcSEcCtD
Guanfacine—Asthenia—Methotrexate—urinary bladder cancer	0.000481	0.0007	CcSEcCtD
Guanfacine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000478	0.000696	CcSEcCtD
Guanfacine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000474	0.000691	CcSEcCtD
Guanfacine—Pruritus—Methotrexate—urinary bladder cancer	0.000474	0.00069	CcSEcCtD
Guanfacine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000462	0.000672	CcSEcCtD
Guanfacine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000459	0.000668	CcSEcCtD
Guanfacine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000458	0.000667	CcSEcCtD
Guanfacine—Asthenia—Epirubicin—urinary bladder cancer	0.00045	0.000655	CcSEcCtD
Guanfacine—Pruritus—Epirubicin—urinary bladder cancer	0.000444	0.000646	CcSEcCtD
Guanfacine—Dizziness—Methotrexate—urinary bladder cancer	0.000443	0.000645	CcSEcCtD
Guanfacine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000429	0.000624	CcSEcCtD
Guanfacine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000427	0.000622	CcSEcCtD
Guanfacine—Vomiting—Methotrexate—urinary bladder cancer	0.000426	0.00062	CcSEcCtD
Guanfacine—Rash—Methotrexate—urinary bladder cancer	0.000423	0.000615	CcSEcCtD
Guanfacine—Dermatitis—Methotrexate—urinary bladder cancer	0.000422	0.000614	CcSEcCtD
Guanfacine—Headache—Methotrexate—urinary bladder cancer	0.00042	0.000611	CcSEcCtD
Guanfacine—Asthenia—Doxorubicin—urinary bladder cancer	0.000416	0.000606	CcSEcCtD
Guanfacine—Dizziness—Epirubicin—urinary bladder cancer	0.000415	0.000604	CcSEcCtD
Guanfacine—Pruritus—Doxorubicin—urinary bladder cancer	0.000411	0.000597	CcSEcCtD
Guanfacine—Vomiting—Epirubicin—urinary bladder cancer	0.000399	0.00058	CcSEcCtD
Guanfacine—Nausea—Methotrexate—urinary bladder cancer	0.000398	0.000579	CcSEcCtD
Guanfacine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000397	0.000578	CcSEcCtD
Guanfacine—Rash—Epirubicin—urinary bladder cancer	0.000395	0.000575	CcSEcCtD
Guanfacine—Dermatitis—Epirubicin—urinary bladder cancer	0.000395	0.000575	CcSEcCtD
Guanfacine—Headache—Epirubicin—urinary bladder cancer	0.000393	0.000572	CcSEcCtD
Guanfacine—Dizziness—Doxorubicin—urinary bladder cancer	0.000384	0.000558	CcSEcCtD
Guanfacine—Nausea—Epirubicin—urinary bladder cancer	0.000372	0.000542	CcSEcCtD
Guanfacine—Vomiting—Doxorubicin—urinary bladder cancer	0.000369	0.000537	CcSEcCtD
Guanfacine—Rash—Doxorubicin—urinary bladder cancer	0.000366	0.000532	CcSEcCtD
Guanfacine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000366	0.000532	CcSEcCtD
Guanfacine—Headache—Doxorubicin—urinary bladder cancer	0.000364	0.000529	CcSEcCtD
Guanfacine—Nausea—Doxorubicin—urinary bladder cancer	0.000345	0.000502	CcSEcCtD
Guanfacine—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	4.54e-05	0.00339	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	4.43e-05	0.0033	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	4.29e-05	0.0032	CbGpPWpGaD
Guanfacine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	4.14e-05	0.00309	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	3.65e-05	0.00272	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	3.6e-05	0.00268	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.51e-05	0.00261	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	3.26e-05	0.00243	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.22e-05	0.0024	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.2e-05	0.00238	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	3.11e-05	0.00231	CbGpPWpGaD
Guanfacine—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	3e-05	0.00224	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	2.98e-05	0.00222	CbGpPWpGaD
Guanfacine—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.96e-05	0.0022	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.94e-05	0.00219	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2.92e-05	0.00218	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2.84e-05	0.00212	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.83e-05	0.00211	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTZ1—urinary bladder cancer	2.82e-05	0.0021	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—IFNA2—urinary bladder cancer	2.77e-05	0.00206	CbGpPWpGaD
Guanfacine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	2.74e-05	0.00204	CbGpPWpGaD
Guanfacine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.7e-05	0.00201	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTO2—urinary bladder cancer	2.68e-05	0.00199	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—NAT1—urinary bladder cancer	2.68e-05	0.00199	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—UGT2B7—urinary bladder cancer	2.45e-05	0.00182	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.39e-05	0.00178	CbGpPWpGaD
Guanfacine—ADRA2B—G alpha (i) signalling events—CXCL8—urinary bladder cancer	2.38e-05	0.00177	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	2.36e-05	0.00176	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYP4B1—urinary bladder cancer	2.2e-05	0.00164	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2.16e-05	0.00161	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HDAC4—urinary bladder cancer	2.13e-05	0.00159	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—IFNA2—urinary bladder cancer	2.1e-05	0.00157	CbGpPWpGaD
Guanfacine—ADRA2B—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.08e-05	0.00155	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—SLC19A1—urinary bladder cancer	2.08e-05	0.00155	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PRSS3—urinary bladder cancer	2.03e-05	0.00151	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2e-05	0.00149	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—PLAU—urinary bladder cancer	1.96e-05	0.00146	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.96e-05	0.00146	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.94e-05	0.00144	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	1.9e-05	0.00141	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NAT1—urinary bladder cancer	1.9e-05	0.00141	CbGpPWpGaD
Guanfacine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.89e-05	0.00141	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.86e-05	0.00139	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.82e-05	0.00136	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.81e-05	0.00135	CbGpPWpGaD
Guanfacine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.8e-05	0.00134	CbGpPWpGaD
Guanfacine—ADRA2A—G alpha (i) signalling events—CXCL8—urinary bladder cancer	1.8e-05	0.00134	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—GLI1—urinary bladder cancer	1.79e-05	0.00133	CbGpPWpGaD
Guanfacine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.78e-05	0.00133	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	1.73e-05	0.00129	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.73e-05	0.00129	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.73e-05	0.00129	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.7e-05	0.00127	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—TYMP—urinary bladder cancer	1.62e-05	0.00121	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—CREBBP—urinary bladder cancer	1.62e-05	0.00121	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HDAC4—urinary bladder cancer	1.62e-05	0.00121	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—IGF1—urinary bladder cancer	1.6e-05	0.00119	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.58e-05	0.00118	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.58e-05	0.00118	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	1.56e-05	0.00116	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PLAU—urinary bladder cancer	1.49e-05	0.00111	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	1.47e-05	0.0011	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—NAT2—urinary bladder cancer	1.47e-05	0.00109	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—RHOA—urinary bladder cancer	1.47e-05	0.00109	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR ligand binding—CXCL8—urinary bladder cancer	1.44e-05	0.00107	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	1.44e-05	0.00107	CbGpPWpGaD
Guanfacine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.43e-05	0.00107	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.42e-05	0.00106	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—GLI1—urinary bladder cancer	1.36e-05	0.00101	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.34e-05	0.001	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.31e-05	0.000976	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—RRM2—urinary bladder cancer	1.27e-05	0.000943	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—IL2—urinary bladder cancer	1.23e-05	0.000917	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—CREBBP—urinary bladder cancer	1.23e-05	0.000916	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—RBX1—urinary bladder cancer	1.22e-05	0.000913	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—IGF1—urinary bladder cancer	1.21e-05	0.000905	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.2e-05	0.000896	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—HPGDS—urinary bladder cancer	1.17e-05	0.000874	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ENO2—urinary bladder cancer	1.17e-05	0.000874	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.15e-05	0.000859	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TSC1—urinary bladder cancer	1.15e-05	0.000858	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.15e-05	0.000856	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.14e-05	0.00085	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.14e-05	0.00085	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTT1—urinary bladder cancer	1.14e-05	0.000847	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—RHOA—urinary bladder cancer	1.11e-05	0.000829	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—EP300—urinary bladder cancer	1.1e-05	0.000823	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.1e-05	0.000822	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—JAG1—urinary bladder cancer	1.1e-05	0.000817	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	1.09e-05	0.000814	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—SRC—urinary bladder cancer	1.07e-05	0.0008	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.05e-05	0.000783	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.05e-05	0.000781	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.04e-05	0.000777	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.04e-05	0.000774	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.01e-05	0.00075	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	9.47e-06	0.000706	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—NQO1—urinary bladder cancer	9.45e-06	0.000704	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.39e-06	0.0007	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—IL2—urinary bladder cancer	9.33e-06	0.000696	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—RBX1—urinary bladder cancer	9.29e-06	0.000692	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—RHOA—urinary bladder cancer	9.27e-06	0.000691	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	8.97e-06	0.000668	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—KRAS—urinary bladder cancer	8.89e-06	0.000662	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—S100B—urinary bladder cancer	8.88e-06	0.000661	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.87e-06	0.000661	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TSC1—urinary bladder cancer	8.74e-06	0.000651	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.64e-06	0.000644	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—RHOA—urinary bladder cancer	8.41e-06	0.000627	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—EP300—urinary bladder cancer	8.37e-06	0.000624	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—JAG1—urinary bladder cancer	8.32e-06	0.00062	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	8.3e-06	0.000619	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	8.3e-06	0.000619	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.26e-06	0.000615	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	8.18e-06	0.000609	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—SRC—urinary bladder cancer	8.14e-06	0.000607	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	8.13e-06	0.000606	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	8.05e-06	0.0006	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—NCOR1—urinary bladder cancer	7.98e-06	0.000595	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.93e-06	0.000591	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TP53—urinary bladder cancer	7.9e-06	0.000589	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTP1—urinary bladder cancer	7.88e-06	0.000587	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—IL2—urinary bladder cancer	7.77e-06	0.000579	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	7.57e-06	0.000564	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	7.57e-06	0.000564	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—HRAS—urinary bladder cancer	7.55e-06	0.000563	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.53e-06	0.000561	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—CXCL8—urinary bladder cancer	7.39e-06	0.00055	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	7.34e-06	0.000547	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—TYMS—urinary bladder cancer	7.33e-06	0.000546	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	7.24e-06	0.00054	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	7.24e-06	0.00054	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.23e-06	0.000539	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—IL2—urinary bladder cancer	7.06e-06	0.000526	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TERT—urinary bladder cancer	7.03e-06	0.000524	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	7.03e-06	0.000524	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GPX1—urinary bladder cancer	6.94e-06	0.000517	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.91e-06	0.000515	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	6.81e-06	0.000507	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	6.74e-06	0.000503	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	6.73e-06	0.000502	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	6.69e-06	0.000499	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.49e-06	0.000484	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—FGFR3—urinary bladder cancer	6.45e-06	0.000481	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	6.4e-06	0.000477	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	6.38e-06	0.000476	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ESR1—urinary bladder cancer	6.27e-06	0.000467	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.25e-06	0.000466	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.17e-06	0.00046	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.1e-06	0.000455	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	6.06e-06	0.000451	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	5.99e-06	0.000447	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.92e-06	0.000441	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	5.9e-06	0.00044	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	5.73e-06	0.000427	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.66e-06	0.000422	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	5.6e-06	0.000418	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	5.58e-06	0.000416	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	5.49e-06	0.000409	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	5.43e-06	0.000404	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.4e-06	0.000403	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	5.4e-06	0.000402	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.39e-06	0.000402	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	5.36e-06	0.000399	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	5.34e-06	0.000398	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	5.19e-06	0.000387	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	5.19e-06	0.000387	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.16e-06	0.000385	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	5.13e-06	0.000382	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	5.13e-06	0.000382	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	5.1e-06	0.00038	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.09e-06	0.000379	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.99e-06	0.000372	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.99e-06	0.000372	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	4.99e-06	0.000372	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	4.97e-06	0.00037	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.93e-06	0.000367	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.91e-06	0.000366	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	4.9e-06	0.000365	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.84e-06	0.000361	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.82e-06	0.000359	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	4.76e-06	0.000354	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.73e-06	0.000353	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.68e-06	0.000349	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.68e-06	0.000349	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	4.6e-06	0.000343	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	4.53e-06	0.000338	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.48e-06	0.000334	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.4e-06	0.000328	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	4.36e-06	0.000325	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	4.34e-06	0.000323	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	4.17e-06	0.000311	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.17e-06	0.000311	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.13e-06	0.000308	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	4.12e-06	0.000307	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.1e-06	0.000305	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	4.08e-06	0.000304	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	4.07e-06	0.000303	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.03e-06	0.0003	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	3.95e-06	0.000294	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.93e-06	0.000293	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	3.92e-06	0.000292	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	3.87e-06	0.000288	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	3.77e-06	0.000281	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	3.74e-06	0.000279	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.68e-06	0.000274	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	3.64e-06	0.000271	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	3.56e-06	0.000265	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.53e-06	0.000263	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.49e-06	0.00026	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.4e-06	0.000253	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.36e-06	0.00025	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.35e-06	0.00025	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.31e-06	0.000247	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.29e-06	0.000245	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	3.26e-06	0.000243	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.22e-06	0.00024	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	3.19e-06	0.000238	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	3.16e-06	0.000236	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.12e-06	0.000233	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.09e-06	0.00023	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.09e-06	0.00023	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	3.08e-06	0.00023	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	3.01e-06	0.000225	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	2.99e-06	0.000223	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.98e-06	0.000222	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	2.98e-06	0.000222	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.95e-06	0.00022	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.9e-06	0.000216	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.89e-06	0.000216	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	2.84e-06	0.000212	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	2.76e-06	0.000206	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.73e-06	0.000203	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	2.68e-06	0.0002	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.64e-06	0.000197	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	2.56e-06	0.000191	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.52e-06	0.000188	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.47e-06	0.000184	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.42e-06	0.00018	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.41e-06	0.000179	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.3e-06	0.000171	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.29e-06	0.00017	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.21e-06	0.000165	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.19e-06	0.000163	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.12e-06	0.000158	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	2.03e-06	0.000151	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.94e-06	0.000145	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.74e-06	0.00013	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.52e-06	0.000113	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.45e-06	0.000108	CbGpPWpGaD
